We are a June 30 fiscal year company, and we finished June 30, 2011 with revenues of $402 million. That represented an operating profit of $158 million. The company generates significant cash, $189 million of positive cash flow. And we apply that cash not only to reinvest in the company, but we completed a $200 million stock repurchase program as well. If you look at healthcare today, it’s very effective in the United States but it’s not very efficient. There is fragmented decision making, waste that goes on in the healthcare system, we don’t always know if an individual should be treated so there are unnecessary treatments. And I will talk a little bit about one of our products, PROLARIS, in prostate cancer, where there are many unnecessary surgeries that men take as the don’t know how aggressive their cancer is.And Myriad’s solution to this is to develop products that prevent disease, an ounce of prevention is worth a pound of cure, so we lower cost by preventing the disease in the first place rather than waiting for an individual to contract the disease and then treat the disease. By diagnosing earlier when the treatment is more effective and the survival rate is more effective, and by guiding therapies for the individual’s genetic makeup so that they receive an optimal treatment regime.
Myriad Genetics' CEO Presents At 30th Annual J.P. Morgan Healthcare Conference (Transcript)
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.